Further studies have shown that soluble EphA2-Fc and EphA3-Fc receptor constructs inhibit tumour angiogenesis and growth in vivo (Brantley et al, 2002), providing the first functional evidence for EphA receptor regulation of tumour angiogenesis. Here, EPHA3 is linked to neoplasm.